Camrelizumab plus apatinib CohortA

Phase 2

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR (JHPCY)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

JHPCYPhase 2$38.2B

Camrelizumab plus apatinib CohortA Phase 2 Est. Readout

Camrelizumab plus apatinib CohortA• Gestational Trophoblastic Neoplasia70

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Gestational Trophoblastic Neoplasia

View Full Landscape

Drug Information

Target Indication

Gestational Trophoblastic Neoplasia

Clinical Trial

NCT05139095

Last updated: 8/19/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

JHPCY

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR

Biotechnology•North America•NASDAQ

Related Pipeline

SHR-1209Phase 3

Primary Hypercholesterolemia

PyrotinibPhase 3

HER2-positive Breast Cancer

HRS-9190Phase 3

Neuromuscular Blockade

RocuroniumPhase 3

Neuromuscular Blockade

apatinibPhase 3

Non-Small-Cell Lung Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts